TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37488627

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sound therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of two treatments (from the above options)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single treatment (from the above options)
Number of subjects: 0
Study: 37488632

Group type: EXPERIMENTAL
Intervention: SAIA implementation led by district health managers
Number of subjects: 85
Study: 37488734

Group type: EXPERIMENTAL
Intervention: holo beta-lactoglobulin lozenge (holoBLG) 2x daily for 3 months
Number of subjects: 35
Study: 37488811

Group type: EXPERIMENTAL
Intervention: Risankizumab (150 mg at weeks 0 and 4)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Apremilast (30 mg twice daily)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Switching to risankizumab after 16 weeks of apremilast
Number of subjects: 352

Group type: COMPARATOR
Intervention: Continuing apremilast after 16 weeks
Number of subjects: 352
Study: 37489066

Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg, tremelimumab 75 mg, cisplatin 80 mg/m²
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Durvalumab with tremelimumab and chemotherapy
Number of subjects: 16
Study: 37489096

Group type: EXPERIMENTAL
Intervention: Urgency syndrome
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Satisfaction with sleep
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Physical health
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Physical aspects of QoL
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Psychological aspects of QoL
Number of subjects: 247
Study: 37489374

Group type: EXPERIMENTAL
Intervention: Sirolimus treatment
Number of subjects: 0
Study: 37489724

Group type: EXPERIMENTAL
Intervention: Complete Revascularization (CR)
Number of subjects: 5054
Study: 37489744

Group type: EXPERIMENTAL
Intervention: Ig20Gly (Cuvitru®; Baxalta US, Inc.; part of Takeda, MA, U.S.A.)
Number of subjects: 75
Study: 37489818

Group type: EXPERIMENTAL
Intervention: Antiplatelets plus standard care
Number of subjects: 17541
Study: 37489819

Group type: EXPERIMENTAL
Intervention: FDA approved drugs matched to genomic targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDA approved drugs used outside their approved indications
Number of subjects: 0
Study: 37489991

Group type: EXPERIMENTAL
Intervention: AI-derived body composition measurements from LDCT scans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cox proportional hazards models without AI-derived body composition measurements
Number of subjects: 0
Study: 37489992

Group type: EXPERIMENTAL
Intervention: US and MRI fusion-targeted biopsies with systematic random prostate biopsies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systematic random prostate biopsies alone
Number of subjects: 0
Study: 37490017

Group type: EXPERIMENTAL
Intervention: VRRS HomeKit (teleneuro-VRRS group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual territorial rehabilitative treatments (UTRTs; control group)
Number of subjects: 40
Study: 37490069

Group type: EXPERIMENTAL
Intervention: HEMR (Histologic Endoscopic Mucosal Remission)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HEMI (Histologic Endoscopic Mucosal Improvement) without HEMR
Number of subjects: 0

Group type: COMPARATOR
Intervention: HEMR and HEMI
Number of subjects: 0
Study: 37490079

Group type: EXPERIMENTAL
Intervention: FPIA PET
Number of subjects: 10
Study: 37490085

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin (90 mg/kg/d) and clavulanate (6.4 mg/kg/d) for 10 days (n=254)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Placebo for 10 days (n=256)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin and clavulanate
Number of subjects: 515
Study: 37490086

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 544

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 544
Study: 37490100

Group type: EXPERIMENTAL
Intervention: Back pain model
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Disability model
Number of subjects: 452
Study: 37490202

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37490268

Group type: EXPERIMENTAL
Intervention: CAL/BDP PAD-cream
Number of subjects: 0
Study: 37490291

Group type: EXPERIMENTAL
Intervention: Recombinant human prourokinase (rhPro-UK)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 663
Study: 37490292

Group type: EXPERIMENTAL
Intervention: Plasma ctDNA testing with next-generation sequencing (NGS) assay before lung cancer diagnosis
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard tissue genotyping after tissue diagnosis (reference cohort)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Plasma ctDNA testing
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tissue NGS
Number of subjects: 150
Study: 37490337

Group type: EXPERIMENTAL
Intervention: Digital physical therapy (home exercise, education, CBT, device with movement digitalization, asynchronous monitoring)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional physical therapy (in-person exercises, manual therapy, education, CBT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups (digital and conventional)
Number of subjects: 82
Study: 37490459

Group type: EXPERIMENTAL
Intervention: Menstrual cup
Number of subjects: 436

Group type: COMPARATOR
Intervention: Control
Number of subjects: 436
Study: 37490604

Group type: EXPERIMENTAL
Intervention: Flavored polyethylene glycol and sulfate solution (FPSS)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Oral sulfate solution (OSS)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Both FPSS and OSS
Number of subjects: 500
Study: 37490693

Group type: EXPERIMENTAL
Intervention: Blocking Aldosterone Synthesis
Number of subjects: 0
Study: 37490738

Group type: EXPERIMENTAL
Intervention: Tailored communication messages from healthcare workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 37490742

Group type: EXPERIMENTAL
Intervention: Intervention package (diagnostic tests, diagnostic algorithm, training-and-communication package)
Number of subjects: 1718

Group type: COMPARATOR
Intervention: Standard practice (control)
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Intervention package
Number of subjects: 1718
Study: 37490745

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 761)
Number of subjects: 1512
Study: 37490916

Group type: EXPERIMENTAL
Intervention: TIL therapy
Number of subjects: 0
Study: 37490939

Group type: EXPERIMENTAL
Intervention: Nano-curcumin (40 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 37490981

Group type: EXPERIMENTAL
Intervention: Telehealth (TH)
Number of subjects: 847

Group type: COMPARATOR
Intervention: In-person (IP)
Number of subjects: 847
Study: 37491084

Group type: EXPERIMENTAL
Intervention: Smartphone-based virtual reality relaxation (S-VR) using 360° panoramic video content and music relaxation intervention through a VR device for ±10 minutes plus standard care
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Smartphone-based virtual reality relaxation (S-VR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Guided imagery relaxation therapy in the form of a leaflet plus standard care
Number of subjects: 80
Study: 37491088

Group type: EXPERIMENTAL
Intervention: Daptomycin (10 mg/kg/d for 8 days)
Number of subjects: 72
Study: 37491104

Group type: EXPERIMENTAL
Intervention: efavaleukin alfa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rozibafusp alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37491149

Group type: EXPERIMENTAL
Intervention: Closed-loop spinal cord stimulation
Number of subjects: 134

Group type: COMPARATOR
Intervention: Open-loop spinal cord stimulation
Number of subjects: 134
Study: 37491196

Group type: EXPERIMENTAL
Intervention: Labor pain intensity (measured by A-LPQ subscale on birthing pain)
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Increased blood loss during delivery (for every 10ml change)
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Presence of shoulder dystocia
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Use of pethidine for labor analgesia
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Having nausea during menstruation before current pregnancy (sometimes)
Number of subjects: 880
Study: 37491199

Group type: EXPERIMENTAL
Intervention: Gap balancing technique
Number of subjects: 225

Group type: COMPARATOR
Intervention: Measured resection technique
Number of subjects: 225
Study: 37491216

Group type: EXPERIMENTAL
Intervention: Telemental health services (components delivered via telephonic or other communication technology for outreach and consultation/coping skills; in-person for intake/assessment and crisis response)
Number of subjects: 500

Group type: COMPARATOR
Intervention: In-person crisis prevention and intervention services (all components delivered in-person)
Number of subjects: 500
Study: 37491235

Group type: EXPERIMENTAL
Intervention: Current coffee consumers
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Cups of coffee consumed per day
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Current coffee consumption
Number of subjects: 213

Group type: COMPARATOR
Intervention: Former and never coffee consumers
Number of subjects: 213
Study: 37491264

Group type: EXPERIMENTAL
Intervention: Home-based contact management with TPT initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Facility-based contact management
Number of subjects: 0
Study: 37491309

Group type: EXPERIMENTAL
Intervention: TAK-228 (4 mg) and TAK-117 (200 mg) orally each day for 3 days followed by 4 days off, weekly, until disease progression (PD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2) and nab paclitaxel therapy post PIKTOR
Number of subjects: 10
Study: 37491373

Group type: EXPERIMENTAL
Intervention: MOv18 IgE antibody (dose escalation from 70 μg to 12 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MOv18 IgE antibody
Number of subjects: 0
Study: 37491482

Group type: EXPERIMENTAL
Intervention: miR ratios (miR-199a-3p_let-7a-5p, miR-26b-5p_miR-142-5p, let-7b-5p_miR-19b-3p, miR-101-3p_miR-19b-3p, miR-93-5p_miR-19b-3p, let-7a-5p_miR-22-3p, miR-21-5p_miR-23a-3p) assessed by RT-qPCR
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI), menopausal status (MS), interaction term BMI*MS, life-style score, breast density
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (66 controls)
Number of subjects: 131
Study: 37491568

Group type: EXPERIMENTAL
Intervention: OSA treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: No OSA treatment or discontinued treatment
Number of subjects: 40
Study: 37491619

Group type: EXPERIMENTAL
Intervention: nHFOV
Number of subjects: 60

Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 60
Study: 37491693

Group type: EXPERIMENTAL
Intervention: LFLG-pEF AS patients without atrial fibrillation (AF)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: LFLG-pEF AS patients with atrial fibrillation (AF)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: LFLG-pEF AS patients with AF
Number of subjects: 444

Group type: COMPARATOR
Intervention: LFLG-pEF AS patients without AF
Number of subjects: 444
Study: 37491889

Group type: EXPERIMENTAL
Intervention: Lurbinectedin + ATR inhibitor berzosertib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lurbinectedin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATR inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: High CDKN1A/p21 expression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increased levels of ERCC5/XPG
Number of subjects: 0

Group type: COMPARATOR
Intervention: MYC-driven non-neuroendocrine tumors
Number of subjects: 0
Study: 37491938

Group type: EXPERIMENTAL
Intervention: zuranolone 50 mg/day
Number of subjects: 196

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 196
Study: 37492067

Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid antagonist)
Number of subjects: 12
Study: 37492087

Group type: EXPERIMENTAL
Intervention: Qiangli Dingxuan tablet combined with amlodipine besylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37492633

Group type: EXPERIMENTAL
Intervention: Oral paclitaxel (oPAC) with encequidar (E) administered at 205 mg/m
Number of subjects: 28
Study: 37492635

Group type: EXPERIMENTAL
Intervention: Weekly reminders
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 26
Study: 37492673

Group type: EXPERIMENTAL
Intervention: Confounder-adjusted MRI features
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: GBM models from confounder-adjusted volumetric MRI features
Number of subjects: 646
Study: 37492907

Group type: EXPERIMENTAL
Intervention: Emollient baths at 2 months
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Emollient baths and frequent emollient application at 2 months
Number of subjects: 1505
Study: 37492920

Group type: EXPERIMENTAL
Intervention: Ligelizumab 24 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ligelizumab 120 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 37492970

Group type: EXPERIMENTAL
Intervention: Endovascular therapy with successful reperfusion (Thrombolysis in Cerebral Infarction score, 2b/3)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Endovascular therapy with successful reperfusion at attempts 1
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Endovascular therapy with >2 recanalization attempts
Number of subjects: 348
Study: 37492976

Group type: EXPERIMENTAL
Intervention: 5-ASA co-treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vedolizumab without 5-ASA
Number of subjects: 0
Study: 37493020

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy for <12 months
Number of subjects: 7159

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy for 12 to <24 months
Number of subjects: 7159

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy for 24 to <36 months
Number of subjects: 7159

Group type: COMPARATOR
Intervention: Beta-blocker therapy for ≥36 months
Number of subjects: 7159

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy for <36 months
Number of subjects: 7159
Study: 37493095

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 11156
Study: 37493229

Group type: EXPERIMENTAL
Intervention: Vaginal probiotic suppository
Number of subjects: 147

Group type: COMPARATOR
Intervention: Without vaginal probiotic suppository (Control)
Number of subjects: 147
Study: 37493253

Group type: EXPERIMENTAL
Intervention: Rolling resistance reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propulsion training
Number of subjects: 0
Study: 37493269

Group type: EXPERIMENTAL
Intervention: RSV/6120/ΔNS2/1030s vaccine (105 PFU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 37493287

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham injections (sodium chloride 0.9%)
Number of subjects: 50
Study: 37493538

Group type: EXPERIMENTAL
Intervention: Vaginal procedures
Number of subjects: 6705

Group type: COMPARATOR
Intervention: Sacral colpopexy
Number of subjects: 6705

Group type: COMPARATOR
Intervention: Transvaginal mesh
Number of subjects: 6705

Group type: COMPARATOR
Intervention: Laparoscopic approach
Number of subjects: 6705

Group type: COMPARATOR
Intervention: Vaginal hysteropexy
Number of subjects: 6705

Group type: COMPARATOR
Intervention: Absorbable sutures
Number of subjects: 6705
Study: 37493673

Group type: EXPERIMENTAL
Intervention: Digital microscope (NGENUITY 3D visualisation system)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional microscope
Number of subjects: 128
Study: 37493759

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Aerobic Exercise (AER)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Combination Training (COMB)
Number of subjects: 186
Study: 37493898

Group type: EXPERIMENTAL
Intervention: Multi-component intervention for lowering high blood pressure (non-pharmacological, based on Disease Control Priorities)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 240
Study: 37493932

Group type: EXPERIMENTAL
Intervention: MedViewer (MV) intervention providing real-time adherence feedback using IR-MALDESI mass spectrometry imaging of daily ART concentrations in hair.
Number of subjects: 36
Study: 37494014

Group type: EXPERIMENTAL
Intervention: Liraglutide, 3.0 mg, once daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 37494051

Group type: EXPERIMENTAL
Intervention: Proactive dashboard-directed telehealth clinics
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study: 37494101

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (1 mg/kg) as an adjunct to sedation protocol
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 mcg/kg) and midazolam (2 mg)
Number of subjects: 66
Study: 37494103

Group type: EXPERIMENTAL
Intervention: Brief counseling approaches (high-intensity and low-intensity) delivered remotely by phone or video call
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Brief counseling approaches (high-intensity and low-intensity)
Number of subjects: 19
Study: 37494106

Group type: EXPERIMENTAL
Intervention: App-delivered socioemotional intervention (Affect Dyad)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Mindfulness-based training
Number of subjects: 218

Group type: COMPARATOR
Intervention: Waitlist control group (received socioemotional training after postintervention assessment)
Number of subjects: 218
Study: 37494112

Group type: EXPERIMENTAL
Intervention: AI-powered doctor
Number of subjects: 64

Group type: COMPARATOR
Intervention: Human-controlled doctor
Number of subjects: 64
Study: 37494277

Group type: EXPERIMENTAL
Intervention: Tissue fibrocytes
Number of subjects: 0
Study: 37494306

Group type: EXPERIMENTAL
Intervention: Challenging Horizons Program (CHP)
Number of subjects: 186
Study: 37494485

Group type: EXPERIMENTAL
Intervention: TAK-994 30 mg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: TAK-994 90 mg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: TAK-994 180 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 37494586

Group type: EXPERIMENTAL
Intervention: Clinically Integrated Breastfeeding Peer Counseling (ci-BPC)
Number of subjects: 720
Study: 37494942

Group type: EXPERIMENTAL
Intervention: Bictegravir (50 mg), Emtricitabine (200 mg), Tenofovir Alafenamide (25 mg)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Dolutegravir (50 mg), Emtricitabine (200 mg), Tenofovir Disoproxil Fumarate (300 mg)
Number of subjects: 243
Study: 37495019

Group type: EXPERIMENTAL
Intervention: GABA supplementation for 95 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 37495197

Group type: EXPERIMENTAL
Intervention: Deep artificial neural networks (DNNs) with data augmentation strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modern DNNs using augmentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: U-Nets and vision transformers
Number of subjects: 0
Study: 37495274

Group type: EXPERIMENTAL
Intervention: Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD)
Number of subjects: 1643
Study: 37495276

Group type: EXPERIMENTAL
Intervention: Combination lipid-lowering therapy (rosuvastatin 10 mg plus ezetimibe 10 mg)
Number of subjects: 72050

Group type: COMPARATOR
Intervention: High-intensity statin monotherapy (rosuvastatin 20 mg)
Number of subjects: 72050
Study: 37495350

Group type: EXPERIMENTAL
Intervention: IVUS guidance by experienced operators
Number of subjects: 6005

Group type: COMPARATOR
Intervention: IVUS guidance by less experienced operators
Number of subjects: 6005
Study: 37495352

Group type: EXPERIMENTAL
Intervention: Sirolimus-Coated Balloon (SCB)
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Sirolimus-Coated Balloon (SCB) in ISR cohort
Number of subjects: 2123
Study: 37495367

Group type: EXPERIMENTAL
Intervention: Acetate and propionate supplementation in a murine model of emphysema
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Acetate supplementation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Asymptomatic smokers
Number of subjects: 26

Group type: COMPARATOR
Intervention: Smokers with emphysema
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of microbiome and metabolome
Number of subjects: 26

Group type: COMPARATOR
Intervention: Higher acetate level in emphysema group
Number of subjects: 26
Study: 37495797

Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (DCB)
Number of subjects: 758

Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: DCB
Number of subjects: 758

Group type: COMPARATOR
Intervention: DES
Number of subjects: 758
Study: 37496001

Group type: EXPERIMENTAL
Intervention: Palliative care program including training for staff and on-site specialty consultations
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Palliative care attitudes and practices assessed through surveys of nursing home staff
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative implementation data including fidelity assessments and interviews with Palliative Care Leads
Number of subjects: 16
Study: 37496004

Group type: EXPERIMENTAL
Intervention: Afamelanotide 16 mg implants administered subcutaneously on Day 0, Day 1, and repeated on Day 7 and Day 8 if not well recovered.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Afamelanotide 16 mg implants administered subcutaneously.
Number of subjects: 6
Study: 37496117

Group type: EXPERIMENTAL
Intervention: Normothermic regional perfusion (NRP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine perfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viability testing of extended criteria donors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative strategies including machine perfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rapid controlled DCD recovery
Number of subjects: 0